NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

First you need a way to actually prove a tumor is shrinking in the face of tumor infiltrating lymphocytes causing an expansion signature. They have a pretty good way to do that now but not then.
Secondly, dividing up indications allows for more specific combos for tumor type when it comes to L and those combos will have different costs involved and different demand rate for treatment. Uniform price for treatment may not be required because of this but also because monotherapy treatment effect with L may be different with regard to quality life years and allowable reimbursement rate based on that.
Third, the automated systems for L do not appear to fit the requirements needed for conserving adherent cells that are produced. With Direct there is obviously equipment that can be considered for lease or purchase based on statements from management. No “me too” equipment mentioned by NWBO for L, rather just the opposite with regard to protecting adherent cells. Best wishes.